StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Equities research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other research firms have also weighed in on CTSO. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Down 1.9 %

CTSO opened at $1.02 on Tuesday. The business has a 50-day moving average of $0.94 and a two-hundred day moving average of $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59. The stock has a market capitalization of $55.77 million, a price-to-earnings ratio of -2.83 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same quarter last year, the business earned ($0.21) EPS. On average, research analysts expect that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of large investors have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents during the third quarter valued at about $51,000. Sargent Investment Group LLC increased its holdings in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.